Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system

Definitions

• the present invention relates to pharmaceutical compositions for treating diabetic neuropathy comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent.
• Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.
• BAY 43-9006 refers to 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy ⁇ -pyridine-2- carboxylic acid methyl amide and is species of diaryl urea compounds which are potent anti-cancer and anti-angiogenic agents that possess various activities, including inhibitory activity on the VEGFR, PDGFR, raf, p38, and/or flt-3 kinase signaling molecules. See, e.g., WO 2004/113274 and WO 2005/000284.
• Diabetic neuropathy also called painful diabetic neuropathy is a common diabetes related phenomenon. Pain as syndrome of neuropathy may be seen in as many as one third of all patients with diabetes. Neuropathic pain is difficult to manage and the available treatment options rarely provide total relief (CF. Corbett, The Diabetes Educator, Vol. 31, 2005, 4, 523-540). Its cause is unclear and it does not respond well to traditional pain therapies (R.A. Malik (2003) Treat. Endocrinol. 2(6), 339-400).
• neuropathic pain Recent advancements in the diagnosis of neuropathic pain include methods that can distinguish between neuropathic and non-neuropathic pain. In the absence of treatment, nerve damage may progress while pain diminishes.
• Symptom mangament treatment is available and includes the use of analgesics (NSAIDs), antidepressants (e.g. selective serotonin reuptake inhibitors, tricyclic antidepressants), anticonvulsants, capsicain topical cream, nexiletine, as well as physical or mechanical therapy such as electrical stimulation, acupuncture, magnet therapy or topical use of polyurethane films.
• NSAIDs analgesics
• antidepressants e.g. selective serotonin reuptake inhibitors, tricyclic antidepressants
• anticonvulsants e.g. selective serotonin reuptake inhibitors, tricyclic antidepressants
• capsicain topical cream e.g. selective serotonin reuptake inhibitors, tricyclic antide
• NMV reduced nerve conduction velocity
• the present invention provides pharmaceutical compositions for treating diabetic neuropathy comprising at least one compound of formula I and optionally at least one further therapeutic agent.
• the present invention provides a therapeutic method which do not only reduce the neuropathic pain of patients more effectively compared to current therapies but also provides a therapeutic method for the reconstitution of nerve functions.
• the therapeutic method according to the invention is superior to current therapies. Therefore the present invention can be used e.g. by administering a diaryl urea compound of formula I and optionally a further therapeutic agent, pharmaceutically-acceptable salts thereof, and derivatives thereof, etc.
• R is hydroxy, C M alkyl, Cj -4 alkoxy or NR 3 R b ,
• R a and R b are independently :
• a heteroaryl group selected from pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, benzoxazole, isoquioline, quinolines and imidazopyrimidine
• heterocyclic group selected from tetrahydropyran, tetrahydrofuran, 1,3- dioxolane, l',4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidone, pentamethylene sulfide, tetramethylene sulfide, dihydropyrane, dihydrofuran, and dihydro- thiophene,
• A is optionally substituted phenyl, pyridinyl, naphthyl, benzoxazole, isoquioline, quinoline or imidazopyrimidine;
• B is optionally substituted phenyl or naphthyl:
• L is a bridging group which is -S- or -O-;
• M is 0,1,2 or 3
• each R 2 is independently Q. 5 alkyl, C 1 . 5 haloalkyl, C 1 . 3 alkoxy, N-oxo or N-hydroxy.
• Structures of optionally substituted phenyl moieties for A of formula (I) which are of particular interest include structures of formula lxx:
• Structures of optionally substituted naphthyl moieties for A of formula (I) which are of particular interest include structures of formula Iy:
• the structure Iy represents that the substituents R 3 can appear on any carbon atom in either ring which has a valence that is otherwise complete with a hydrogen atom as a substituent.
• the bond to the urea group can also be through any carbon atom on either ring which has a valence that is otherwise complete with a hydrogen atom as a substituent.
• B is optionally substituted phenyl or naphthyl.
• Structures of optionally substituted phenyl or naphthyl moieties for B of formula (I) which are of particular interest include structures 2a and 2b:
• the structures 2a and 2b represent that the substituents R 1 can appear on any carbon atom in the structure which has a valence that is otherwise complete with a hydrogen atom as a substituent and the bond to the urea group can be through any carbon atom in the structure which has a valence that is otherwise complete with a hydrogen atom as a substituent.
• B is substituted by at least one halogen substituent.
• R x is NR 3 R b
• R 3 and Rb are independently hydrogen or C M alkyl optionally substituted by hydroxy and L is a bridging group which is -S- or -O-.
• the variable p is 0, 1, 2, 3, or 4, typically 0 or 1.
• the variable n is 0, 1, 2, 3, 4, 5 or 6, typically 0,1 ,2,3 or 4.
• the variable m is 0,1,2 or 3, typically 0.
• Each R 1 is independently: halogen, C,. 5 haloalkyl, NO 2 , C(O)NR 4 R 5 , C 1-6 alkyl, C 1-6 dialkylamine, Ci -3 alkylamine, CN, amino, hydroxy or Ci -3 alkoxy. Where present, R 1 is more commonly halogen and of the halogens, typically chlorine or fluorine, and more commonly fluorine.
• Each R 2 is independently: Ci -5 alkyl, Ci -5 haloalkyl, Q -3 alkoxy, N-oxo or N-hydroxy. Where present, R 2 is typically methyl or trifluoromethyl.
• Each R 3 is independently selected from halogen, R 4 , OR 4 , S(O)R 4 , C(O)R 4 , C(O)NR 4 R 5 , oxo, cyano or nitro (NO 2 ).
• R 4 and R 5 are independently selected from hydrogen, Q -6 alkyl, and up to per-halogenated Ci -6 alkyl.
• A examples include: 3-tert butyl phenyl, 5-tert butyl-2-methoxyphenyl,
• the urea group -NH-C(O)-NH- and the bridging group, L are not bound to contiguous ring carbons of B, but rather have 1 or 2 ring carbons separating them.
• R 1 groups include fluorine, chorine, bromine, methyl, NO 2 , C(O)NH 2 , methoxy, SCH 3 , trifluoromethyl, and methanesulfonyl.
• R 2 groups include methyl, ethyl, propyl, oxygen, and cyano.
• R 3 groups include trifluoromethyl, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl, chlorine, fluorine, bromine, cyano, methoxy, acetyl, trifluoromethanesulfonyl, trifiuoromethoxy, and trifluoromethylthio.
• Ra and Rb are independently hydrogen and Q-C 4 alkyl
• urea group, -NH-C(O)-NH-, and the oxygen bridging group are not bound to contiguous ring carbons of B, but rather have 1 or 2 ring carbons separating them,
• a of formula (II) is wherein the variable n is 0, 1, 2, 3 or 4.
• R 3 is trifluoromethyl, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl, chlorine, fluorine, bromine, cyano, methoxy, acetyl, trifluoromethanesulfbnyl, trifluoromethoxy, or trifluoromethylthio.
• each R 3 substituent on A of formula II is selected from chlorine, trifluoromethyl, tert-butyl or methoxy.
• a of formula II is
• B of formula II is phenylene, fluoro substituted phenylene or difluoro substituted phenylene.
• Another class of compounds of interest includes compounds having the structure of formulae X below wherein phenyl ring "B” optionally has one halogen substituent.
• R 2 , m and A are as defined above for formula I.
• the variable "m” is preferably zero, leaving C(O)NHCH 3 as the only substituent on the pyridinyl moiety.
• Preferred values for A are substituted phenyl which have at least one substituent, R 3 .
• R 3 is preferably halogen, preferably CI or F, trifluoromethyl and/or methoxy.
• a subclass of compounds of interest includes compounds having the structure of formulas Zl and Z2 below :
• compound of formula I is 4 ⁇ 4-[3-(4-chloro-3- trifluoromethylphenyl)-ureido]-phenoxy ⁇ -pyridine-2-carboxylic acid methyl amide (BAY 43-
• the p-toluenesulfonic acid salt of 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]- phenoxy ⁇ -pyridine-2-carboxylic acid methyl amide (tosylate salt of compound (I)). More preferably the p-toluenesulfonic acid salt of 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]- phenoxy ⁇ -pyridine-2-carboxylic acid methyl amide exists for at least 80% in the stable polymorph I.
• the p-toluenesulfonic acid salt of 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylphenyl)- ureido]-phenoxy ⁇ -pyridine-2-carboxylic acid methyl amide exists for at least 80% in the stable polymorph I and in a micronized form.
• Micronization can be achieved by standard milling methods, preferably by air chat milling, known to a skilled person.
• the micronized form can have a mean particle size of from 0.5 to 10 ⁇ m, preferably from 1 to 6 ⁇ m, more preferably from 1 to 3 ⁇ m.
• the indicated particle size is the mean of the particle size distribution measured by laser diffraction known to a skilled person (measuring device: HELOS, Sympatec).
• any moiety When any moiety is "substituted", it can have up to the highest number of indicated substituents and each substituent can be located at any available position on the moiety and can be attached through any available atom on the substituent. "Any available position” means any position on the moiety that is chemically accessible through means known in the art or taught herein and that does not create an unstable molecule, e.g., incapable of administration to a human. When there are two or more substituents on any moiety, each substituent is defined independently of any other substituent and can, accordingly, be the same or different.
• hydroxy as a pyridine substituent includes 2-, 3-, and 4- hydroxypyridine, and also includes those structures referred to in the art as 1 -oxo-pyridine, 1- hydroxy-pyridine or pyridine N-oxide.
• Cr 6 alkyl means straight, branched chain or cyclic alkyl groups having from one to six carbon atoms, which may be cyclic, linear or branched with single or multiple branching. Such groups include for example methyl, ethyl, ⁇ -propyl, isopropyl, n- butyl, isobutyl, sec-butyl, ferf-butyl, cyclopropyl, cyclobutyl and the like.
• Cp 6 haloalkyl means a saturated hydrocarbon radical having up to six carbon atoms, which is substituted with a least one halogen atom, up to perhalo.
• the radical may be cyclic, linear or branched with single or multiple branching.
• the halo substituent(s) include fluoro, chloro, bromo, or iodo. Fluoro, chloro and bromo are preferred, and fluoro and chloro are more preferred.
• the halogen substituent(s) can be located on any available carbon. When more than one halogen substituent is present on this moiety, they may be the same or different. Examples of such halogenated alkyl substituents include but are not limited to chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl,
• Ci- 6 alkoxy means a cyclic, straight or branched chain alkoxy group having from one to six saturated carbon atoms which may be cyclic, linear or branched with single or multiple branching, and includes such groups as methoxy, ethoxy, n- propoxy, isopropoxy, butoxy, pentoxy and the like. It also includes halogenated groups such as 2, 2-dichloroethoxy, trifluoromethoxy, and the like.
• Halo or halogen means fluoro, chloro, bromo, or iodo. Fluoro, chloro and bromo are preferred, and fluoro and chloro are more preferred.
• Ci- 3 alkylamine means methylamino, ethylamino, propylamino or isopropylamino.
• Examples of Cp 6 dialkylamine include but are not limited to diethylamino, ethyl-isopropylamino, methyl-isobutylamino and dihexylamino.
• heteroaryl refers to both monocyclic and bicyclic heteroaryl rings.
• Monocyclic heteroaryl means an aromatic monocyclic ring having 5 to 6 ring atoms and 1-4 hetero atoms selected from N, O and S, the remaining atoms being carbon. When more than one hetero atom is present in the moiety, they are selected independently from the other(s) so that they may be the same or different.
• Monocyclic heteroaryl rings include, but are not limited to pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, and triazine.
• Bicyclic heteroaryl means fused bicyclic moieties where one of the rings is chosen from the monocyclic heteroaryl rings described above and the second ring is either benzene or another monocyclic heteroaryl ring described above. When both rings in the bicyclic moiety are heteroaryl rings, they may be the same or different, as long as they are chemically accessible by means known in the art.
• Bicyclic heteroaryl rings include synthetically accessible 5-5, 5-6, or 6-6 fused bicyclic aromatic structures including, for example but not by way of limitation, benzoxazole (fused phenyl and oxazole), quinoline (fused phenyl and pyridine), imidazopyrimidine (fused imidazole and pyrimidine), and the like.
• the bicyclic heteroaryl moieties may be partially saturated.
• the second ring as described above is either fully or partially saturated or both rings are partially saturated.
• 5 or 6 membered heterocyclic ring, containing at least one atom selected from oxygen, nitrogen and sulfur, which is saturated, partially saturated, or aromatic includes, by no way of limitation, tetrahydropyran, tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidone, pentamethylene sulfide, tetramethylene sulfide, dihydropyrane, dihydrofuran, dihydrothiophene, pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, and the like.
• Cp 3 alkyl-phenyl includes, for example, 2-methylphenyl, isopropylphenyl, 3- phenylpropyl, or 2-phenyl-l-methylethyl. Substituted examples include 2-[2-chlorophenylJethyl, 3,4-dimethylphenylmethyl, and the like.
• aryl includes 6-12 membered mono or bicyclic aromatic hydrocarbon groups (e.g., phenyl, naphthalene, azulene, indene group ) having 0, 1, 2, 3, 4, 5 or 6 substituents.
• the compounds of formula (I) may contain one or more asymmetric centers, depending upon the location and nature of the various substituents desired.
• Asymmetric carbon atoms may be present in the (R) or (S) configuration or (R 1 S) configuration. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds. Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the present invention.
• Preferred compounds are those with the absolute configuration of the compound of formula (I) which produces the more desirable biological activity.
• Separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. The purification of said isomers and the separation of said isomeric mixtures can be accomplished by standard techniques known in the art.
• the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
• appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid.
• Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallization.
• the optically active bases or acids are then liberated from the separated diastereomeric salts.
• a different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivation, optimally chosen to maximize the separation of the enantiomers.
• Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable.
• Enzymatic separations, with or without derivitization, are also useful.
• the optically active compounds of formula I can likewise be obtained by chiral syntheses utilizing optically active starting materials.
• the present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts, metabolites and prodrugs .
• pharmaceutically acceptable salt refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19.
• Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
• Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, mangnesium, ammonium, and choline salts.
• acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
• alkali and alkaline earth metal salts are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
• Representative salts of the compounds of this invention include the conventional non-toxic salts and the quaternary ammonium salts which are formed, for example, from inorganic or organic acids or bases by means well known in the art.
• acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesulfonate,
• Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine. Additionally, basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aryl or aralkyl halides like benzyl and phenethyl bromides and others monosubstituted aralkyl halides or polysubstituted aralkyl
• Solvates for the purposes of the invention are those forms of the compounds where solvent molecules form a complex in the solid state and include, but are not limited to for example ethanol and methanol. Hydrates are a specific form of solvates, where the solvent molecule is water.
• Certain pharmacologically active agents can be further modified with labile functional groups that are cleaved after in vivo administration to furnish the parent active agent and the pharmacologically inactive derivatizing group.
• These derivatives commonly referred to as prodrugs, can be used, for example, to alter the physicochemical properties of the active agent, to target the active agent to a specific tissue, to alter the pharmacokinetic and pharmacodynamic properties of the active agent, and to reduce undesirable side effects.
• Prodrugs of the invention include, e.g., the esters of appropriate compounds of this invention that are well-tolerated, pharmaceutically acceptable esters such as alkyl esters including methyl, ethyl, propyl, isopropyl, butyl, isobutyl or pentyl esters. Additional esters such as phenyl-Ci-C 5 alkyl may be used, although methyl ester is preferred.
• esters of appropriate compounds of this invention that are well-tolerated, pharmaceutically acceptable esters such as alkyl esters including methyl, ethyl, propyl, isopropyl, butyl, isobutyl or pentyl esters. Additional esters such as phenyl-Ci-C 5 alkyl may be used, although methyl ester is preferred.
• the metabolites of the compounds of this invention include oxidized derivatives of the compounds of formula I, II, X, Zl and Z2, wherein one or more of the nitrogens are substituted with a hydroxy group; which includes derivatives where the nitrogen atom of the pyridine group is in the oxide form, referred to in the art as 1 -oxo-pyridine or has a hydroxy substituent, referred to in the art as 1 -hydroxy-pyridine.
• the compounds of the invention may be prepared by use of known chemical reactions and procedures as described in the following published international applications WO 00/42012, WO03/047579, WO 2005/009961, WO 2004/078747 and WO05/000284 and European patent applications EP 04023131.8 and EP 04023130.0.
• the compounds of the invention can be made according to conventional chemical methods, and/or as disclosed below, from starting materials which are either commercially available or producible according to routine, conventional chemical methods. General methods for the preparation of the compounds are given below.
• ureas of formula (I) can be prepared from the condensation of the two arylamine fragments and in the presence of phosgene, di-phosgene, tri-phosgene, carbonyldiimidazole, or equivalents in a solvent that does not react with any of the starting materials, as described in one or more of these published.
• compounds of formula (I) can be synthesized by reacting amino compounds) with isocyanate compounds as described in one or more of the published international applications described above.
• the isocyanates are commercially available or can be synthesized from heterocyclic amines according to methods commonly known to those skilled in the art [e.g. from treatment of an amine with phosgene or a phosgene equivalent such as trichloromethyl chloroformate (diphosgene), bis(trichloromethyl)carbonate (triphosgene), or N,N'-carbonyldiimidazole (CDI); or, alternatively by a Curtius-type rearrangement of an amide, or a carboxylic acid derivative, such as an ester, an acid halide or an anhydride].
• phosgene or a phosgene equivalent such as trichloromethyl chloroformate (diphosgene), bis(trichloromethyl)carbonate (triphosgene), or N,N'-carbonyldiimidazole (CDI); or, alternatively by a Curtius-type rearrangement of an amide, or a carboxy
• Aryl amines of formulas are commercially available, or can be synthesized according to methods commonly known to those skilled in the art.
• Aryl amines are commonly synthesized by reduction of nitroaryls using a metal catalyst, such as Ni, Pd, or Pt, and H 2 or a hydride transfer agent, such as formate, cyclohexadiene, or a borohydride (Rylander. Hydrogenation Methods; Academic Press: London, UK (1985)).
• Nitroaryls may also be directly reduced using a strong hydride source, such as LiAlH 4 (Seyden-Penne.
• Pyridine- 1 -oxides of formula (I) where the pyridine ring carries a hydroxy substituent on its nitrogen atom, and A, B, L are broadly defined as above can be prepared from the corresponding pyridines using oxidation conditions know in the art. Some examples are as follows:
• peracids such as meta chloroperbenzoic acids in chlorinated solvents such as dichloromethane, dichloroethane, or chloroform (Markgraf et al., Tetrahedron 1991, 47, 183);
• Synthetic transformations that may be employed in the synthesis of compounds of formula (I) and in the synthesis of intermediates involved in the synthesis of compounds of formula (I) are known by or accessible to one skilled in the art. Collections of synthetic transformations may be found in compilations, such as:
• the compounds of formula I according to the present invention can be combined with further therapeutic agents such as analgesics, anti-depressants, anti-diabetics, glucose controlling agents, neuroprotective agents, anticonvulsants, anesthesics, anti-inflammatory agents or capsaicin.
• further therapeutic agents such as analgesics, anti-depressants, anti-diabetics, glucose controlling agents, neuroprotective agents, anticonvulsants, anesthesics, anti-inflammatory agents or capsaicin.
• analgesics include, but are not limited to, NSAID (non-steroidal antiinflammatory drugs), COX-I- or COX-2-inhibitors etc..
• NSAID examples include, but are not limited to, e.g. aceclofenac, acetaminophen, o- acetylsalicylic acid, alclofenac, alminprofen, amfenac, ampiroxicam, amtolmetinguacil, anirolac, antrafenin, azapropazon, benorilat, bermoprofen, bindarit, bromfenac, bucloxsaure, bucolom, bufexamac, bumadizon, butibufen, butixirat, carbasalat calcium, carprofen, cinmetacin, cinnoxicam, clidanac, clobuzarit, deboxamet, dexibuprofen, dexketoprofen, diclofenac, diflunisal, eltenac, enfenamsaure, etersalat, etodolac, etofenamat
• an NSAID selected from the group consisting of acetaminophen, o- acetylsalicylic acid, clidanac, diclofenac, flurbiprofen, ibuprofen, ketoprofen and sulindac. More preferably o-acetylsalicylic acid is used as NSAID.
• anesthesics include, but are not limited to, e.g. melixetine, lidocaine and benzocaine. Preference is given to melixetine.
• anti-depressants include, but are not limited to, selective serotonin reuptake inhibitors or tricyclic anti-depressants, e.g. duloxetine, trazodone and venlafaxine.
• anticonvulsants include, but are not limited to, gabapentin, lamotrigine, amitriptyline and pregabalin.
• anti-diabetic agents include, but are not limited to, e.g. insuline, CB-I antagonists such as rimonabant or SLV-319, 5HT uptake inhibitors such as sibutramin, lipase inhibitors such as orlistat or ALT-962, CNTF agonists such as axokine, DGAT inhibitors such as BAY 74-4113, DPP rV inhibitors such as vildagliptin, sitagliptin, saxagliptin, LAF-237, MK-0431 or BMS- 477118, GLP-I analogues such as exenatide, betatropin, BIM-51077, CJC-1 131 or liraglutide, PPAR ⁇ agonists such as BAY 62-9069, BAY 68-2959, tesaglitazar, muraglitazar, ONO-5129, LY-510929, LY-519818, GW-67
• the compounds and combinations according to the present invention can be used for manufacture of a medicament for treating diabetic neuropathy.
• the present invention provides methods of treating diabetic neuropathy, comprising administering effective amounts of at least one compound of formula I and optionally at least one further therapeutic agent according to the invention.
• An "effective amount" is the quantity of the compound that is useful to achieve the desired result, e.g., to treat the disease or condition.
• Diabetic neuropathy is also known as painful diabetic neuropathy.
• Compounds or drug combinations of the present invention can be administered in any form by any effective route, including, e.g., oral, parenteral, enteral, intravenous, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, and intrathecal, etc. They can be administered alone, or in combination with any ingredient(s), active or inactive.
• any effective route including, e.g., oral, parenteral, enteral, intravenous, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, and intrathecal, etc. They can be administered alone, or in
• Compounds or drug combinations of the present invention can be converted in a known manner into the usual formulations, which may be liquid or solid formulations e.g. without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions.
• formulations which may be liquid or solid formulations e.g. without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions.
• the combinations of the present invention can be administered at any time and in any effective form.
• the compounds can be administered simultaneously, e.g., as a single composition or dosage unit (e.g., a pill or liquid containing both compositions), or they can be administered as separate compositions, but at the same time (e.g., where one drug is administered intravenously and the other is administered orally or intramuscularly).
• the drugs can also be administered sequentially at different times.
• Agents can be formulated conventionally to achieve the desired rates of release over extended period of times, e.g., 12-hours, 24-hours. This can be achieved by using agents and/or their derivatives which have suitable metabolic half-lives, and/or by using controlled release formulations.
• the drug combinations can be synergistic, e.g., where the joint action of the drugs is such that the combined effect is greater than the algebraic sum of their individual effects.
• reduced amounts of the drugs can be administered, e.g., reducing toxicity or other deleterious or unwanted effects, and/or using the same amounts as used when the agents are administered alone, but achieving greater efficacy.
• additives include any of the substances already mentioned, as well as any of those used conventionally, such as those described in Remington: The Science and Practice of Pharmacy (Gennaro and Gennaro, eds, 20th edition,
• compounds or drug combinations of the present invention can be administered with other active agents or other therapies that are utilized to treat any of the above-mentioned diseases and/or conditions.
• therapies according to the invention include, but are not limited to, physical or mechanical therapy such as electrical stimulation, acupuncture, magnet therapy or topical use of polyurethane films.
• the present invention provides also combinations of at least one compound of Formula I and at least one other therapeutic agent mentioned above useful in treating a disease or disorder.
• “Combinations” for the purposes of the invention include:
• compositions or dosage forms which contain at least one compound of Formula I and at least one other therapeutic agent mentioned above;
• -kits which comprise at least one compound of Formula I and at least one other therapeutic agent mentioned above packaged separate from one another as unit dosages or as independent unit dosages, with or without instructions that they be administered concurrently or sequentially;
• each agent of the combination can be selected with reference to the other and/or the type of disease and/or the disease status in order to provide the desired therapeutic activity.
• the active agents in the combination can be present and administered in a fixed combination.
• "Fixed combination” is intended here to mean pharmaceutical forms in which the components are present in a fixed ratio that provides the desired efficacy. These amounts can be determined routinely for a particular patient, where various parameters are utilized to select the appropriate dosage (e.g., type of disease, age of patient, disease status, patient health, weight, etc.), or the amounts can be relatively standard.
• the amount of the administered active ingredient can vary widely according to such considerations as the particular compound and dosage unit employed, the mode and time of administration, the period of treatment, the age, sex, and general condition of the patient treated, the nature and extent of the condition treated, the rate of drug metabolism and excretion, the potential drug combinations and drug-drug interactions, and the like.
• an amount of p-toluenesulfonic acid salt of 4 ⁇ 4-[3-(4-chloro-3- trifIuoromethyIphenyl)-ureido]-phenoxy ⁇ -pyridine-2-carboxylic acid methyl amide in the pharmaceutical composition from 27 to 2740 mg, preferably from 54 to 1096, more preferably from 68 to 822 mg.
• the compound of formula I is administered in combination with at least one further therapeutic agent in an amount that those of ordinary skill in the art can determine by their professional judgement.
• the pharmaceutical composition according to the invention is administered one or more, preferably up to three, more preferably up to two times per day. Preference is given to an administration via the oral route. With each administration the number of tablets or capsules taken in at the same time should not exceed two.
• the combination can comprise effective amounts of at least one compound of Formula I and at least one other therapeutic agent mentioned above, which achieves a greater therapeutic efficacy than when either compound is used alone.
• the combination can be useful to treat diabetic neuropathy, where the therapeutic effect is not observed when the agents are used alone, or where an enhanced effect is observed when the combination is administered.
• the relative ratios of each compound in the combination can also be selected based on their respective mechanisms of action and the disease biology.
• the relative ratios of each compound can vary widely and this invention includes combinations for treating diabetic neuropathy where the amounts of the formula I compound and the other therapeutic agent can be adjusted routinely such that either is present in higher amounts.
• the release of one or more agents of the combination can also be controlled, where appropriate, to provide the desired therapeutic activity when in a single dosage form, combination pack, kit or when in separate independent dosage forms.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Pyridine Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=37635833

Family Applications (1)

Country Status (5)

Families Citing this family (3)

Family Cites Families (2)

• 2006
  • 2006-11-09 WO PCT/EP2006/010746 patent/WO2007054302A1/en active Application Filing
  • 2006-11-09 CA CA002628875A patent/CA2628875A1/en not_active Abandoned
  • 2006-11-09 KR KR1020087011172A patent/KR20080066948A/ko not_active Application Discontinuation
  • 2006-11-09 EP EP06828981A patent/EP1948172A1/de not_active Withdrawn
  • 2006-11-09 JP JP2008539335A patent/JP2009514920A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events